Automated USP and EP GPC/SEC Analysis of Low Molecular Weight Heparin (LMWH)
LCGC Asia Pacific
PSS Application Note
Daniela Held, PSS Polymer Standards Service GmbH, Mainz, Germany.
Introduction
LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da. GPC/SEC is the method of choice to measure the molecular weight (molar mass) and the molecular weight fractions above/below a molecular weight limit. Both, the Pharmaeuropa (EP) and the US Pharmacopeia (USP), require GPC/SEC to characterize commercially available LMWHs.
Results
Although the calibration procedures described in the EP and USP are totally different, a dedicated GPC/SEC software can be used to analyse the heparin data in accordance with both standards precisely. Figure 1 shows the final results for the analysis of unknown low molecular weight heparin. PSS WinGPC Unity GPC/SEC software allows 2 markers to be set at 2000 and 8000 Da, to display the measured percent below 2000 Da, above 8000 Da and in between these values.
Figure 1
Of utmost importance is the y-axis of the result window. WinGPC Unity shows a true molar mass distribution with a w(log M) axis. Only this guarantees correct fractions above/below the molecular weight borders 2000 and 8000.3
Table 1: Comparison of experimental conditions from USP and EP for the characterization of LMWH.
References
1. USP Enoxaparin sodium http://www.usp.org/pdf/EN/USPNF/enoxaparinSodium.pdf
2. EP Low-Molecular-Mass (LMM) heparins Monograph 0828.
3. D. Held and P. Kilz; Quantification in LC and GC - A Practical Guide to Good Chromatographic Data [H.-J. Kuss/ S. Kromidas (eds.)], 271–302, Wiley-VCH, Weinheim (2009).
PSS Polymer Standards Service GmbH
In der Dalheimer Weise 5, D-55120 Mainz, Germany
tel. +49 6131 96239 41 fax +49 6131 96239 11
E-mail: DHeld@polymer.de Website: www.polymer.de
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
